Background Erlotinib is an EGFR tyrosine kinase inhibitor that has shown a significant but only marginally improved median overall survival when combined with gemcitabine in patients with locally advanced and metastatic pancreatic cancer. Vandetanib is a novel tyrosine kinase inhibitor of VEGFR2, RET, and EGFR, all of which are in involved in the pathogenesis of pancreatic cancer. We investigated the clinical efficacy of vandetanib when used in combination with gemcitabine in patients with advanced pancreatic cancer.Methods The Vandetanib in Pancreatic Cancer (ViP) trial was a phase 2 double-blind, multicentre, randomised placebo-controlled trial in previously untreated adult patients (aged ≥18 years) diagnosed with locally advanced or meta...
IMPORTANCE: In locally advanced pancreatic cancer, the role of chemoradiotherapy is controversial an...
Objective AIO-PK0104 investigated two treatment strategies in advanced pancreatic cancer (PC): a ref...
Pancreatic carcinoma, a chemoresistant disease, still remains a therapeutic challenge in oncology. A...
Background Erlotinib is an EGFR tyrosine kinase inhibitor that has shown a significant but only marg...
Methods: The Vandetanib in Pancreatic Cancer (ViP) trial was a phase 2 double-blind, multicentre, ra...
BACKGROUND: Erlotinib is an EGFR tyrosine kinase inhibitor that has shown a significant but only mar...
PurposeErlotinib marginally improves survival when administered continuously with gemcitabine to pat...
BACKGROUND: Erlotinib is an EGFR tyrosine kinase inhibitor that has shown a significant but only mar...
To investigate activity, toxicity, and prognostic factors for survival of erlotinib and fixed dose-r...
Importance In locally advanced pancreatic cancer, the role of chemoradiotherapy is controversial and...
Single agent gemcitabine has been the mainstay of therapy for advanced pancreatic cancer over the pa...
Pancreatic adenocarcinoma is a leading cause of cancer death in western countries. The treatment of ...
<div><p>Background</p><p>This study aims to comprehensively summarize the currently available eviden...
BACKGROUND/AIMS: Erlotinib and gemcitabine combined chemotherapy is becoming the treatment of choice...
Yuan Wang,1 Guo-fang Hu,1 Qian-qian Zhang,1 Ning Tang,1 Jun Guo,2 Li-yan Liu,2 Xiao Han,2 Xia Wang,2...
IMPORTANCE: In locally advanced pancreatic cancer, the role of chemoradiotherapy is controversial an...
Objective AIO-PK0104 investigated two treatment strategies in advanced pancreatic cancer (PC): a ref...
Pancreatic carcinoma, a chemoresistant disease, still remains a therapeutic challenge in oncology. A...
Background Erlotinib is an EGFR tyrosine kinase inhibitor that has shown a significant but only marg...
Methods: The Vandetanib in Pancreatic Cancer (ViP) trial was a phase 2 double-blind, multicentre, ra...
BACKGROUND: Erlotinib is an EGFR tyrosine kinase inhibitor that has shown a significant but only mar...
PurposeErlotinib marginally improves survival when administered continuously with gemcitabine to pat...
BACKGROUND: Erlotinib is an EGFR tyrosine kinase inhibitor that has shown a significant but only mar...
To investigate activity, toxicity, and prognostic factors for survival of erlotinib and fixed dose-r...
Importance In locally advanced pancreatic cancer, the role of chemoradiotherapy is controversial and...
Single agent gemcitabine has been the mainstay of therapy for advanced pancreatic cancer over the pa...
Pancreatic adenocarcinoma is a leading cause of cancer death in western countries. The treatment of ...
<div><p>Background</p><p>This study aims to comprehensively summarize the currently available eviden...
BACKGROUND/AIMS: Erlotinib and gemcitabine combined chemotherapy is becoming the treatment of choice...
Yuan Wang,1 Guo-fang Hu,1 Qian-qian Zhang,1 Ning Tang,1 Jun Guo,2 Li-yan Liu,2 Xiao Han,2 Xia Wang,2...
IMPORTANCE: In locally advanced pancreatic cancer, the role of chemoradiotherapy is controversial an...
Objective AIO-PK0104 investigated two treatment strategies in advanced pancreatic cancer (PC): a ref...
Pancreatic carcinoma, a chemoresistant disease, still remains a therapeutic challenge in oncology. A...